Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient herb Gou-Teng put to the test against early memory decline

NCT ID NCT04532697

Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This pilot study tests whether the Chinese herb Uncaria rhynchophylla (Gou-Teng) can slow cognitive decline in people aged 65 and older with mild cognitive impairment. Participants take the herb or a placebo twice daily for 16 weeks, with follow-up for 8 more weeks. Researchers will measure changes in cognitive function and brain health using eye scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a Chinese herbal medicine called Uncaria rhynchophylla (Gou-Teng)
What this could lead to
If effective, this herb could offer a complementary option to slow cognitive decline in older adults with mild cognitive impairment.
What could go wrong
This is a small pilot study, so results may not be conclusive. The herb's benefits and safety are not yet proven, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

56 people

The number who actually took part.

Started

Nov 2020

Finished

Oct 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Both male and female individuals aged 65 years or over at their last birthday * Montreal Cognitive Assessment (Hong Kong version) (HK-MoCA) age/education matched percentile (score), with the cut off score of ≤16th percentile * Understand the questionnaires used in the study * Agreement to give informed consent Exclusion Criteria: * Known dementia including Alzheimer's disease * Current drug use for the treatment of MCI or dementia * Patient Health Questionnaire-9 (PHQ-9) score 15 or more * Known psychiatric diseases such as depressive episode, bipolar disorder, obsessive-compulsive disorder and schizophrenia; * Known history of seizures; * Known history of stroke associated with permanent disability; * Known history of liver and renal impairment; * Known history of allergy to Chinese herbal medicine; * Concomitant use of warfarin or any anti-coagulants * Current history of hazardous or harmful alcohol consumption; * Current medical history that prevented participation in the study tasks such as sensory impairment and advanced cancer; * Current use of any kind of herbal medicine for the prevention and treatment of dementia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild cognitive impairment White matter hyperintensity

Contacts and locations

Locations

  • The Chinese University of Hong Kong

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.